299 related articles for article (PubMed ID: 32707005)
21. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
[TBL] [Abstract][Full Text] [Related]
22. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
Douglas RS
Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804
[TBL] [Abstract][Full Text] [Related]
23. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
Smith TJ
J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
[TBL] [Abstract][Full Text] [Related]
24. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
25. Teprotumumab for thyroid eye disease: early response is not required for benefit.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas RS
Eye (Lond); 2022 Jul; 36(7):1403-1408. PubMed ID: 34183792
[TBL] [Abstract][Full Text] [Related]
26. A Review of Novel Medical Treatments for Thyroid Eye Disease.
Park JW; Yoon JS
Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
[TBL] [Abstract][Full Text] [Related]
27. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
[TBL] [Abstract][Full Text] [Related]
28. The Adverse Effects Profile of Teprotumumab.
Stan MN; Krieger CC
J Clin Endocrinol Metab; 2023 Aug; 108(9):e654-e662. PubMed ID: 37071658
[TBL] [Abstract][Full Text] [Related]
29. Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators.
Douglas RS; Wang Y; Dailey RA; Harris GJ; Wester ST; Schiffman JS; Tang RA; Fowler B; Fleming J; Smith TJ
J Neuroophthalmol; 2021 Dec; 41(4):461-468. PubMed ID: 33417417
[TBL] [Abstract][Full Text] [Related]
30. Ototoxicity and Teprotumumab.
Highland J; Gordon S; Reddy D; Patel N
Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
[TBL] [Abstract][Full Text] [Related]
31. The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials.
Lin F; Yao Q; Yu B; Deng Z; Qiu J; He R
Int J Clin Pract; 2023; 2023():6638089. PubMed ID: 37588100
[TBL] [Abstract][Full Text] [Related]
32. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
[TBL] [Abstract][Full Text] [Related]
33. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
Hwang CJ; Rebollo NP; Mechels KB; Perry JD
Am J Ophthalmol; 2024 Jul; 263():152-159. PubMed ID: 38142982
[TBL] [Abstract][Full Text] [Related]
34. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
Radulovich N; Van Brummen A; Chambers C; Zhang M
Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
[TBL] [Abstract][Full Text] [Related]
35. Teprotumumab for the treatment of thyroid eye disease.
Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
[TBL] [Abstract][Full Text] [Related]
36. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
37. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
[TBL] [Abstract][Full Text] [Related]
38. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
39. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
Chen KW; Phelps PO
Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
[TBL] [Abstract][Full Text] [Related]
40. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.
Smith TJ; Cavida D; Hsu K; Kim S; Fu Q; Barbesino G; Wester ST; Holt RJ; Bhattacharya RK
Ophthalmology; 2024 Jul; 131(7):815-826. PubMed ID: 38253291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
